Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

8.080 +0.120 (+1.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
 
Via Benzinga
NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the... 
Via StockStory
NeoGenomics Reports First Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
Earnings Scheduled For April 29, 2025
 
Via Benzinga
Insights Ahead: NeoGenomics's Quarterly Earnings
 
Via Benzinga
Demystifying NeoGenomics: Insights From 6 Analyst Reviews
 
Via Benzinga
NeoGenomics (NEO) Q1 Earnings Report Preview: What To Look For
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings tomorrow morning. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
Deep Dive Into NeoGenomics Stock: Analyst Perspectives (5 Ratings)
 
Via Benzinga
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
From NeoGenomics, Inc.
Via Business Wire
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting... 
Via StockStory
NeoGenomics Completes Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers. 
Via StockStory
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
From NeoGenomics, Inc.
Via Business Wire
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack
Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers. 
Via StockStory
Q4 Testing & Diagnostics Services Earnings: RadNet (NASDAQ:RDNT) Impresses
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting... 
Via StockStory
3 Reasons to Sell NEO and 1 Stock to Buy Instead
NeoGenomics has gotten torched over the last six months - since September 2024, its stock price has dropped 36.8% to $9.98 per share. This may have investors wondering how to approach the situation. 
Via StockStory
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
From NeoGenomics, Inc.
Via Business Wire
Earnings Scheduled For March 18, 2025
 
Via Benzinga
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst... 
Via StockStory
3 Small-Cap Stocks in Hot Water
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
3 Healthcare Stocks Skating on Thin Ice
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
What To Expect From RadNet’s (RDNT) Q4 Earnings
Diagnostic imaging company RadNet (NASDAQ:RDNT) will be reporting results tomorrow after market hours. Here’s what to look for. 
Via StockStory
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
Why NeoGenomics (NEO) Shares Are Trading Lower Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall... 
Via StockStory
NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, the... 
Via StockStory
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. 
Via StockStory
Earnings Scheduled For February 18, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.